Physician profile
Alexis Lincoln
NPI 1326629775
$10,322.84
in general payments reported to CMS, 2019-2025
34 companies · $3,593 in 2025
The $3,593 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $675 · 2023: $2,596 · 2024: $3,460 · 2025: $3,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,841 · Travel and Lodging: $668 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,841.08 |
| Travel and Lodging | $668.21 |
| Education | $138.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,352.70 | 2022-2025 | |
| Amgen INC. | $1,379.02 | 2023-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $1,168.86 | 2022-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $942.65 | 2023-2025 | Taltz, Zepbound |
| Janssen Biotech, INC. | $799.29 | 2022-2025 | Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $698.20 | 2025 | |
| Pfizer INC. | $451.56 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $303.91 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $274.75 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $255.07 | 2024-2025 | |
| Radius Health, INC. | $239.84 | 2022-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $227.63 | 2024-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $172.88 | 2022-2024 | Ultomiris, Strensiq |
| Fresenius Kabi USA, LLC | $109.17 | 2023-2025 | Idacio |
| Genzyme Corporation | $109.10 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $97.90 | 2023-2025 | Lupkynis |
| Biosense Webster, INC. | $87.31 | 2024 | Carto 3 |
| Kyowa Kirin, INC. | $79.26 | 2023-2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $78.91 | 2022-2025 | Purified Cortrophin Gel |
| Celltrion USA INC. | $64.52 | 2023-2024 | Yuflyma, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.36 | 2023-2024 | Cyltezo, Ofev |
| Genentech USA, INC. | $53.55 | 2025 | Actemra |
| Glaxosmithkline, LLC. | $38.80 | 2023-2025 | Benlysta |
| Horizon Therapeutics Plc | $37.70 | 2023 | Krystexxa |
| Progentec Diagnostics, INC. | $36.25 | 2022 | |
| Octapharma USA, INC. | $34.66 | 2024 | Panzyga |
| Pharming Healthcare, INC. | $30.66 | 2023 | Ruconest |
| Organon LLC | $29.15 | 2025 | Hadlima |
| Allergan, INC. | $28.52 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.09 | 2023 | Truxima |
| Scilex Pharmaceuticals INC. | $17.77 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.76 | 2025 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $14.59 | 2024 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.45 | 2023 | Cuvitru |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Lincoln listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.